BRTX Stock Analysis: Buy, Sell, or Hold?
BRTX - BioRestorative Therapies, Inc. Common Stock (NV)
$2.67
-0.09 (-3.26%)
▼
5d:
+1758.04%
30d:
+1157.65%
90d:
+610.11%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Sep 15, 2026
TODAY
Get Alerted When BRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: BRTX is 76.8% above its trading range ($1.51). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: BRTX is 76.8% above its trading range ($1.51). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: BRTX is currently trading at $2.67, which is considered extended relative to its 30-day fair value range of $-0.32 to $1.51.
Technical Outlook: Technically, BRTX is in a downtrend. Immediate support is located at $0.14, while resistance sits at $3.23. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: BRTX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $160.00 (+5892.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BRTX is in a downtrend. Immediate support is located at $0.14, while resistance sits at $3.23. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: BRTX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $160.00 (+5892.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$-0.32 -
$1.51
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
10.5%
All Signals
- BEARISH: Price significantly overextended (+76.8% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 5892.5% below Wall St target ($160.00)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$-0.32 -
$1.51
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.14
Resistance Level
$3.23
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.26
Wall Street Target
$160.00
(+5892.5%)
Revenue Growth (YoY)
-7.3%
Share & Embed Analysis
Last updated: September 14, 2026 2:15 AM ET
Data refreshes hourly during market hours. Next update: 3:15 AM
Data refreshes hourly during market hours. Next update: 3:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$849 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$290 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$34 | 52 HOLD |
